Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - water for injections, quantity: 5.4 ml - injection, solution - excipient ingredients: - adynovate is a long-acting antihaemophilic factor (recombinant) indicated in haemophilia a (congenital factor viii deficiency) patients for:,? control and prevention of bleeding episodes,? routine prophylaxis to prevent or reduce the frequency of bleeding episodes,? perioperative management (surgical prophylaxis),adynovate is not indicated for the treatment of von willebrand disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - water for injections, quantity: 5.4 ml - injection, solution - excipient ingredients: - adynovate is a long-acting antihaemophilic factor (recombinant) indicated in haemophilia a (congenital factor viii deficiency) patients for:,? control and prevention of bleeding episodes,? routine prophylaxis to prevent or reduce the frequency of bleeding episodes,? perioperative management (surgical prophylaxis),adynovate is not indicated for the treatment of von willebrand disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - water for injections, quantity: 5.4 ml - injection, solution - excipient ingredients: - adynovate is a long-acting antihaemophilic factor (recombinant) indicated in haemophilia a (congenital factor viii deficiency) patients for:,? control and prevention of bleeding episodes,? routine prophylaxis to prevent or reduce the frequency of bleeding episodes,? perioperative management (surgical prophylaxis),adynovate is not indicated for the treatment of von willebrand disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - guanfacine hydrochloride, quantity: 4.56 mg - tablet, modified release - excipient ingredients: hypromellose; methacrylic acid - ethyl acrylate copolymer (1:1); sodium lauryl sulfate; polysorbate 80; microcrystalline cellulose; colloidal anhydrous silica; lactose; povidone; crospovidone; glycerol dibehenate; fumaric acid; indigo carmine aluminium lake; iron oxide yellow - intuniv is indicated for the treatment of attention deficit hyperactivity disorder (adhd) in children and adolescents 6-17 years old, as monotherapy (when stimulants or atomoxetine are not suitable, not tolerated or have been shown to be ineffective) or as adjunctive therapy to psychostimulants (where there has been a sub-optimal response to psychostimulants).intuniv must be used as part of a comprehensive adhd management programme, typically including psychological, educational and social measures.

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - guanfacine hydrochloride, quantity: 3.42 mg - tablet, modified release - excipient ingredients: hypromellose; methacrylic acid - ethyl acrylate copolymer (1:1); sodium lauryl sulfate; polysorbate 80; microcrystalline cellulose; colloidal anhydrous silica; lactose; povidone; crospovidone; glycerol dibehenate; fumaric acid; indigo carmine aluminium lake; iron oxide yellow - intuniv is indicated for the treatment of attention deficit hyperactivity disorder (adhd) in children and adolescents 6-17 years old, as monotherapy (when stimulants or atomoxetine are not suitable, not tolerated or have been shown to be ineffective) or as adjunctive therapy to psychostimulants (where there has been a sub-optimal response to psychostimulants).intuniv must be used as part of a comprehensive adhd management programme, typically including psychological, educational and social measures.

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - guanfacine hydrochloride, quantity: 2.28 mg - tablet, modified release - excipient ingredients: hypromellose; methacrylic acid - ethyl acrylate copolymer (1:1); sodium lauryl sulfate; polysorbate 80; microcrystalline cellulose; colloidal anhydrous silica; lactose; povidone; crospovidone; glycerol dibehenate; fumaric acid - intuniv is indicated for the treatment of attention deficit hyperactivity disorder (adhd) in children and adolescents 6-17 years old, as monotherapy (when stimulants or atomoxetine are not suitable, not tolerated or have been shown to be ineffective) or as adjunctive therapy to psychostimulants (where there has been a sub-optimal response to psychostimulants).intuniv must be used as part of a comprehensive adhd management programme, typically including psychological, educational and social measures.

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - guanfacine hydrochloride, quantity: 1.14 mg - tablet, modified release - excipient ingredients: hypromellose; methacrylic acid - ethyl acrylate copolymer (1:1); sodium lauryl sulfate; polysorbate 80; microcrystalline cellulose; colloidal anhydrous silica; lactose; povidone; crospovidone; glycerol dibehenate; fumaric acid - intuniv is indicated for the treatment of attention deficit hyperactivity disorder (adhd) in children and adolescents 6-17 years old, as monotherapy (when stimulants or atomoxetine are not suitable, not tolerated or have been shown to be ineffective) or as adjunctive therapy to psychostimulants (where there has been a sub-optimal response to psychostimulants).intuniv must be used as part of a comprehensive adhd management programme, typically including psychological, educational and social measures.

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - water for injections, quantity: 5.4 ml - injection, solution - excipient ingredients: - adynovate is a long-acting antihaemophilic factor (recombinant) indicated in haemophilia a (congenital factor viii deficiency) patients for:,? control and prevention of bleeding episodes,? routine prophylaxis to prevent or reduce the frequency of bleeding episodes,? perioperative management (surgical prophylaxis),adynovate is not indicated for the treatment of von willebrand disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - susoctocog alfa, quantity: 500 u/ml - injection - excipient ingredients: - for the treatment of bleeding episodes in adults with acquired haemophilia a.,safety and efficacy of obizur have not been established in patients with baseline anti- porcine factor viii inhibitor titre greater than 20 bu.,obizur is not indicated for the treatment of congenital haemophilia a or von willebrand disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - nonacog gamma, quantity: 500 iu - injection, powder for - excipient ingredients: histidine; sodium chloride; calcium chloride dihydrate; mannitol; sucrose; polysorbate 80 - 1) routine prophylaxis of bleeding episodes in adults with haemophilia b,2) treatment and prevention of bleeding episodes in adults with haemophilia b (congenital factor ix deficiency),3) peri-operative management in adults with haemophilia b 1) routine prophylaxis of bleeding episodes in patients with haemophilia b 2) treatment and prevention of bleeding episodes in patients with haemophilia b (congenital factor ix deficiency) 3) peri-operative management in patients with haemophilia b